The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials

David L. DeMets, Thomas R. Fleming, Richard J. Whitley, James F. Childress, Susan S. Ellenberg, Mary Foulkes, Kenneth H. Mayer, Judith O'Fallon, Richard B Pollard, James J. Rahal, Merle Sande, Stephen Straus, LeRoy Walters, Patricia Whitley-Williams

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The urgency of the Acquired immune deficiency syndrome (AIDS) epidemic has mandated that multiple therapeutic approaches be developed and that these approaches be evaluated through clinical trials. To oversee these trials, the National Institute of Allergy and Infectious Diseases (NIAID) has created three large clinical trial programs monitored by a Data and Safety Monitoring Board (DSMB). For each clinical trial, this Board uses a standardized approach employing contemporary biostatistical, medical, and ethical principles. The DSMB is responsible for reviewing interim data on clinical trial performance, treatment safety and efficacy, and overall study progress. If interim results provide convincing evidence of either excessive adverse effects or significant treatment benefit, the DSMB may recommend early termination of the trial to the NIAID and the study investigators. The responsibility, organization, and operating procedures of this DSMB are presented and illustrated through three clinical trials sponsored by NIAID and monitored by the Board. The rationale and operational model for the DSMB may be a useful example for the development of similar review processes in other HIV clinical trial settings.

Original languageEnglish (US)
Pages (from-to)408-421
Number of pages14
JournalControlled Clinical Trials
Volume16
Issue number6
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Clinical Trials Data Monitoring Committees
Acquired Immunodeficiency Syndrome
National Institute of Allergy and Infectious Diseases (U.S.)
Clinical Trials
Research Personnel
HIV
Organizations
Safety

Keywords

  • AIDS clinical trials
  • DSMBs

ASJC Scopus subject areas

  • Pharmacology

Cite this

DeMets, D. L., Fleming, T. R., Whitley, R. J., Childress, J. F., Ellenberg, S. S., Foulkes, M., ... Whitley-Williams, P. (1995). The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials. Controlled Clinical Trials, 16(6), 408-421. https://doi.org/10.1016/S0197-2456(95)00073-9

The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials. / DeMets, David L.; Fleming, Thomas R.; Whitley, Richard J.; Childress, James F.; Ellenberg, Susan S.; Foulkes, Mary; Mayer, Kenneth H.; O'Fallon, Judith; Pollard, Richard B; Rahal, James J.; Sande, Merle; Straus, Stephen; Walters, LeRoy; Whitley-Williams, Patricia.

In: Controlled Clinical Trials, Vol. 16, No. 6, 1995, p. 408-421.

Research output: Contribution to journalArticle

DeMets, DL, Fleming, TR, Whitley, RJ, Childress, JF, Ellenberg, SS, Foulkes, M, Mayer, KH, O'Fallon, J, Pollard, RB, Rahal, JJ, Sande, M, Straus, S, Walters, L & Whitley-Williams, P 1995, 'The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials', Controlled Clinical Trials, vol. 16, no. 6, pp. 408-421. https://doi.org/10.1016/S0197-2456(95)00073-9
DeMets, David L. ; Fleming, Thomas R. ; Whitley, Richard J. ; Childress, James F. ; Ellenberg, Susan S. ; Foulkes, Mary ; Mayer, Kenneth H. ; O'Fallon, Judith ; Pollard, Richard B ; Rahal, James J. ; Sande, Merle ; Straus, Stephen ; Walters, LeRoy ; Whitley-Williams, Patricia. / The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials. In: Controlled Clinical Trials. 1995 ; Vol. 16, No. 6. pp. 408-421.
@article{e2c25bae58f44d9d908d19dc7996eda0,
title = "The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials",
abstract = "The urgency of the Acquired immune deficiency syndrome (AIDS) epidemic has mandated that multiple therapeutic approaches be developed and that these approaches be evaluated through clinical trials. To oversee these trials, the National Institute of Allergy and Infectious Diseases (NIAID) has created three large clinical trial programs monitored by a Data and Safety Monitoring Board (DSMB). For each clinical trial, this Board uses a standardized approach employing contemporary biostatistical, medical, and ethical principles. The DSMB is responsible for reviewing interim data on clinical trial performance, treatment safety and efficacy, and overall study progress. If interim results provide convincing evidence of either excessive adverse effects or significant treatment benefit, the DSMB may recommend early termination of the trial to the NIAID and the study investigators. The responsibility, organization, and operating procedures of this DSMB are presented and illustrated through three clinical trials sponsored by NIAID and monitored by the Board. The rationale and operational model for the DSMB may be a useful example for the development of similar review processes in other HIV clinical trial settings.",
keywords = "AIDS clinical trials, DSMBs",
author = "DeMets, {David L.} and Fleming, {Thomas R.} and Whitley, {Richard J.} and Childress, {James F.} and Ellenberg, {Susan S.} and Mary Foulkes and Mayer, {Kenneth H.} and Judith O'Fallon and Pollard, {Richard B} and Rahal, {James J.} and Merle Sande and Stephen Straus and LeRoy Walters and Patricia Whitley-Williams",
year = "1995",
doi = "10.1016/S0197-2456(95)00073-9",
language = "English (US)",
volume = "16",
pages = "408--421",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials

AU - DeMets, David L.

AU - Fleming, Thomas R.

AU - Whitley, Richard J.

AU - Childress, James F.

AU - Ellenberg, Susan S.

AU - Foulkes, Mary

AU - Mayer, Kenneth H.

AU - O'Fallon, Judith

AU - Pollard, Richard B

AU - Rahal, James J.

AU - Sande, Merle

AU - Straus, Stephen

AU - Walters, LeRoy

AU - Whitley-Williams, Patricia

PY - 1995

Y1 - 1995

N2 - The urgency of the Acquired immune deficiency syndrome (AIDS) epidemic has mandated that multiple therapeutic approaches be developed and that these approaches be evaluated through clinical trials. To oversee these trials, the National Institute of Allergy and Infectious Diseases (NIAID) has created three large clinical trial programs monitored by a Data and Safety Monitoring Board (DSMB). For each clinical trial, this Board uses a standardized approach employing contemporary biostatistical, medical, and ethical principles. The DSMB is responsible for reviewing interim data on clinical trial performance, treatment safety and efficacy, and overall study progress. If interim results provide convincing evidence of either excessive adverse effects or significant treatment benefit, the DSMB may recommend early termination of the trial to the NIAID and the study investigators. The responsibility, organization, and operating procedures of this DSMB are presented and illustrated through three clinical trials sponsored by NIAID and monitored by the Board. The rationale and operational model for the DSMB may be a useful example for the development of similar review processes in other HIV clinical trial settings.

AB - The urgency of the Acquired immune deficiency syndrome (AIDS) epidemic has mandated that multiple therapeutic approaches be developed and that these approaches be evaluated through clinical trials. To oversee these trials, the National Institute of Allergy and Infectious Diseases (NIAID) has created three large clinical trial programs monitored by a Data and Safety Monitoring Board (DSMB). For each clinical trial, this Board uses a standardized approach employing contemporary biostatistical, medical, and ethical principles. The DSMB is responsible for reviewing interim data on clinical trial performance, treatment safety and efficacy, and overall study progress. If interim results provide convincing evidence of either excessive adverse effects or significant treatment benefit, the DSMB may recommend early termination of the trial to the NIAID and the study investigators. The responsibility, organization, and operating procedures of this DSMB are presented and illustrated through three clinical trials sponsored by NIAID and monitored by the Board. The rationale and operational model for the DSMB may be a useful example for the development of similar review processes in other HIV clinical trial settings.

KW - AIDS clinical trials

KW - DSMBs

UR - http://www.scopus.com/inward/record.url?scp=0029591767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029591767&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(95)00073-9

DO - 10.1016/S0197-2456(95)00073-9

M3 - Article

C2 - 8720018

AN - SCOPUS:0029591767

VL - 16

SP - 408

EP - 421

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 6

ER -